MedMira invites investment analysts to conference call HALIFAX, June 27 /PRNewswire-FirstCall/ -- MedMira Inc. ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in flow-through diagnostics, today announced that it will host a conference call with analysts to discuss the company's second quarter financial results beginning at 9:30 a.m. Eastern Standard Time (10:30 a.m. Atlantic) on Wednesday, June 29, 2005. The call will be preceded by the release of the company's third quarter financial results the previous evening and they will be available on the MedMira web site http://www.medmira.com/ In order to listen to the conference call, please either dial 800-814-4857 for toll-free anywhere in Canada or the USA, or 416-640-4127 in the Toronto area. A replay of the call will be available until 23:59 ET Wednesday, July 6, 2005 and may be accessed by dialing 877-289-8525 for toll-free anywhere in Canada or the USA, or 416-640-1917 in the Toronto area and entering the pass code: 21129490 followed by the number sign, anytime after the call has been ended. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow-through rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter (OTC) in pharmacies throughout the Hong Kong and Macao Special Administrative Regions, in P.R. China. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Investor Relations, Dr. James Smith: (902) 450-1588 or e-mail:

Copyright